Kentaro Ohki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kentaro Ohki has a total of 330 co-authors. Here are the top co-authors by number of shared publications:
Yasuhide Hayashi
Department of Hematology/Oncology Gunma Children's Medical Center Gunma Japan
8 shared publications- Daisuke Tomizawa
Division of Leukemia and Lymphoma, Children's Cancer Center National Center for Child Health and Development Tokyo Japan
6 shared publications - Nobutaka Kiyokawa
Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan
6 shared publications Takashi Taga
Department of Pediatrics Shiga University of Medical Science Otsu Shiga Japan
6 shared publicationsKeizo Horibe
National Hospital Organization Nagoya Medical Center
5 shared publicationsSouichi Adachi
Department of Human Health Sciences Kyoto University Graduate School of Medicine Kyoto Japan
5 shared publications
Latest Publications
- 10 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1586-1597
Multiomics analysis focusing on genome‐wide DNA methylation in paediatric acute promyelocytic leukaemia
Summary: We conducted a multiomics analysis of paediatric acute promyelocytic leukaemia (APL) in 36 patients enrolled in the Japanese AML‐P05 study. Targeted deep sequencing identified EP300 mutations ( n = 2) and MYC ‐internal tandem duplication (ITD) ( n = 1), which have not been previously reported in APLs. DNA methylation analysis classified 34 paediatric APLs into two groups: hypermethylation and hypomethylation. Patients in the hypermethylation group had significantly worse outcomes compared to those in the hypomethylation group (3‐year overall survival: 80% vs. 100%, p = 0.043; 3‐year event‐free survival: 73% vs. 95%, p = 0.049). Remarkably, the EBF1‐binding motif was enriched in 82.3% of the CpG sites that were differentially methylated between the hyper‐ and hypomethylation groups, and these sites were predominantly located in enhancer regions. Among the 1427 genes that were significantly differentially expressed between the two groups, EP300 was significantly downregulated in the hypermethylation group. Pathway analyses revealed global transcriptional downregulation in the hypermethylation group; however, MYC , a known EP300 ‐repressed gene, was upregulated within the G2M checkpoint. Our findings suggest a potential link among enhancer‐based epigenetic dysregulation involving DNA methylation at EBF1‐binding sites, EP300 dysfunction and MYC activation. These alterations may contribute to disease heterogeneity and prognosis in paediatric APL.
- 10 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1586-1597
Multiomics analysis focusing on genome‐wide DNA methylation in paediatric acute promyelocytic leukaemia
Summary: We conducted a multiomics analysis of paediatric acute promyelocytic leukaemia (APL) in 36 patients enrolled in the Japanese AML‐P05 study. Targeted deep sequencing identified EP300 mutations ( n = 2) and MYC ‐internal tandem duplication (ITD) ( n = 1), which have not been previously reported in APLs. DNA methylation analysis classified 34 paediatric APLs into two groups: hypermethylation and hypomethylation. Patients in the hypermethylation group had significantly worse outcomes compared to those in the hypomethylation group (3‐year overall survival: 80% vs. 100%, p = 0.043; 3‐year event‐free survival: 73% vs. 95%, p = 0.049). Remarkably, the EBF1‐binding motif was enriched in 82.3% of the CpG sites that were differentially methylated between the hyper‐ and hypomethylation groups, and these sites were predominantly located in enhancer regions. Among the 1427 genes that were significantly differentially expressed between the two groups, EP300 was significantly downregulated in the hypermethylation group. Pathway analyses revealed global transcriptional downregulation in the hypermethylation group; however, MYC , a known EP300 ‐repressed gene, was upregulated within the G2M checkpoint. Our findings suggest a potential link among enhancer‐based epigenetic dysregulation involving DNA methylation at EBF1‐binding sites, EP300 dysfunction and MYC activation. These alterations may contribute to disease heterogeneity and prognosis in paediatric APL.
- Open Access
- 26 March 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (13) , 1395-1411
Comprehensive molecular and functional analysis of NUTM1 -rearranged leukemia
NUTM1 rearrangement defines a significant subset of B-cell acute lymphoblastic leukemia (B-ALL), particularly in infants lacking KMT2A rearrangements, yet its underlying molecular characteristics remain poorly understood. Here, we establish that NUTM1-rearranged (NUTM1-r) leukemia is a discrete entity characterized by a unique transcriptional and epigenetic landscape, notably featuring global DNA hypomethylation, irrespective of the 5′ fusion partner. Functional interrogation of NUTM1 fusions reveals a dual oncogenic role: they drive commitment toward the B-lymphoid lineage while concurrently conferring potent leukemic stem cell properties. Strikingly, expression of a representative fusion, BRD9-NUTM1, is sufficient to induce serially transplantable B-cell progenitor, prepro–B-like leukemia in vivo, faithfully recapitulating the key molecular and immunophenotypic features of human NUTM1-r B-ALL. Mechanistically, NUTM1 fusions establish an aberrant chromatin state, marked by global enhancement of H3K27 acetylation and the creation of distinctive open chromatin regions that co-opt both B-lineage and stemness-related transcriptional programs, including those involving NF-κB and posterior HoxA genes. In stark contrast to resistant KMT2A-rearranged leukemias, NUTM1-r leukemic cells exhibit a profound sensitivity to chemotherapy. This vulnerability is mechanistically linked to the leukemia's dependence on active transcription. Our findings delineate the unique molecular profile of NUTM1-r leukemias, revealing specific vulnerabilities that rationalize their favorable clinical outcomes and suggest opportunities for modified therapeutic strategies.
- 26 March 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (13) , 1395-1411
Open AccessComprehensive molecular and functional analysis of NUTM1 -rearranged leukemia
NUTM1 rearrangement defines a significant subset of B-cell acute lymphoblastic leukemia (B-ALL), particularly in infants lacking KMT2A rearrangements, yet its underlying molecular characteristics remain poorly understood. Here, we establish that NUTM1-rearranged (NUTM1-r) leukemia is a discrete entity characterized by a unique transcriptional and epigenetic landscape, notably featuring global DNA hypomethylation, irrespective of the 5′ fusion partner. Functional interrogation of NUTM1 fusions reveals a dual oncogenic role: they drive commitment toward the B-lymphoid lineage while concurrently conferring potent leukemic stem cell properties. Strikingly, expression of a representative fusion, BRD9-NUTM1, is sufficient to induce serially transplantable B-cell progenitor, prepro–B-like leukemia in vivo, faithfully recapitulating the key molecular and immunophenotypic features of human NUTM1-r B-ALL. Mechanistically, NUTM1 fusions establish an aberrant chromatin state, marked by global enhancement of H3K27 acetylation and the creation of distinctive open chromatin regions that co-opt both B-lineage and stemness-related transcriptional programs, including those involving NF-κB and posterior HoxA genes. In stark contrast to resistant KMT2A-rearranged leukemias, NUTM1-r leukemic cells exhibit a profound sensitivity to chemotherapy. This vulnerability is mechanistically linked to the leukemia's dependence on active transcription. Our findings delineate the unique molecular profile of NUTM1-r leukemias, revealing specific vulnerabilities that rationalize their favorable clinical outcomes and suggest opportunities for modified therapeutic strategies.
- Open Access
- 17 March 2025
- Published by Springer Nature in Research Square
PRDM16::SKI is a predictor of aberrant expression of the short variant of PRDM16 in pediatric acute myeloid leukemia
The RNA-sequencing data from the Japanese Children’s Cancer Group (JCCG)’s AML-05 study was re-analyzed to clarify the mechanisms related to high PRDM16 expressions, which is independently associated with adverse outcomes. Results showed that 19 of 139 patients presented with out-of-frame PRDM16::SKI fusions. Thus, the gene expression levels of PRDM16::SKI in 369 and 329 patients from the AML-05 and AML-12 studies, respectively, were measured. In total, 119 (32%) of 369 patients in the AML-05 study and 58 (18%) of 329 patients in the AML-12 study presented with an aberrant expression of PRDM16::SKI. This fusion was a 48-base-pair product that immediately formed a stop codon on the SKI side. The introduction of this product in mice did not cause AML. Intriguingly, none of the patients presented with SKI::PRDM16, which is reciprocal. Moreover, partner fusion genes were not detected in front of truncated PRDM16, indicating that a short form of PRDM16, which lacked exon 1, existed by itself. Patients with high PRDM16::SKI expression had significantly worse overall survival and event-free survival than those with a low PRDM16 expression. The cleavage between exons 1 and 2 of PRDM16 induces aberrant PRDM16 expression, and a strong associations was observed between PRDM16::SKI and PRDM16 expression.
- 17 March 2025
- Published by Springer Nature in Research Square
Open AccessPRDM16::SKI is a predictor of aberrant expression of the short variant of PRDM16 in pediatric acute myeloid leukemia
The RNA-sequencing data from the Japanese Children’s Cancer Group (JCCG)’s AML-05 study was re-analyzed to clarify the mechanisms related to high PRDM16 expressions, which is independently associated with adverse outcomes. Results showed that 19 of 139 patients presented with out-of-frame PRDM16::SKI fusions. Thus, the gene expression levels of PRDM16::SKI in 369 and 329 patients from the AML-05 and AML-12 studies, respectively, were measured. In total, 119 (32%) of 369 patients in the AML-05 study and 58 (18%) of 329 patients in the AML-12 study presented with an aberrant expression of PRDM16::SKI. This fusion was a 48-base-pair product that immediately formed a stop codon on the SKI side. The introduction of this product in mice did not cause AML. Intriguingly, none of the patients presented with SKI::PRDM16, which is reciprocal. Moreover, partner fusion genes were not detected in front of truncated PRDM16, indicating that a short form of PRDM16, which lacked exon 1, existed by itself. Patients with high PRDM16::SKI expression had significantly worse overall survival and event-free survival than those with a low PRDM16 expression. The cleavage between exons 1 and 2 of PRDM16 induces aberrant PRDM16 expression, and a strong associations was observed between PRDM16::SKI and PRDM16 expression.
- Top Cited PapersOpen Access
- 10 February 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (5) , 567-577
JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL
PURPOSE: The JCCG ALL-B12 clinical trial aimed to evaluate the effectiveness of unvalidated treatment phases for pediatric ALL and develop a safety-focused treatment framework. PATIENTS AND METHODS: Patients age 1-19 years with newly diagnosed B-ALL were enrolled in this study. These patients were stratified into standard-risk (SR), intermediate-risk (IR), and high-risk (HR) groups. Randomized comparisons assessed the effectiveness of vincristine (VCR)/dexamethasone pulses in the SR group, evaluated the effects of L-asparaginase (ASP) intensification in the IR group, and compared standard consolidation including block-type treatment with experimental consolidation with high-dose methotrexate (HD-MTX) intensified with VCR and ASP in the HR group. RESULTS: Of 1,936 patients enrolled, 1,804 were eligible for the experimental treatment. The overall 5-year event-free survival and overall survival rates were 85.2% (95% CI, 83.5 to 86.8) and 94.3% (95% CI, 93.1 to 95.3), respectively. The cumulative incidence of relapse and postremission nonrelapse mortality was 13.2% (95% CI, 11.6 to 14.8) and 0.6% (95% CI, 0.3 to 1.0), respectively. Random assignment in the SR group showed no significant benefit from pulse therapy. In the IR group, ASP intensification had limited effects. In the HR group, standard block therapy and HD-MTX yielded equivalent outcomes. CONCLUSION: The ALL-B12 trial achieved favorable outcomes in a nationwide cohort by stratifying treatment on the basis of risk and balancing treatment intensity. This study not only demonstrated that existing standard of care can be further refined but also indicated that improvement in outcomes with intensified chemotherapy has reached a plateau.
- 10 February 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (5) , 567-577
Top Cited PapersOpen AccessJCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL
PURPOSE: The JCCG ALL-B12 clinical trial aimed to evaluate the effectiveness of unvalidated treatment phases for pediatric ALL and develop a safety-focused treatment framework. PATIENTS AND METHODS: Patients age 1-19 years with newly diagnosed B-ALL were enrolled in this study. These patients were stratified into standard-risk (SR), intermediate-risk (IR), and high-risk (HR) groups. Randomized comparisons assessed the effectiveness of vincristine (VCR)/dexamethasone pulses in the SR group, evaluated the effects of L-asparaginase (ASP) intensification in the IR group, and compared standard consolidation including block-type treatment with experimental consolidation with high-dose methotrexate (HD-MTX) intensified with VCR and ASP in the HR group. RESULTS: Of 1,936 patients enrolled, 1,804 were eligible for the experimental treatment. The overall 5-year event-free survival and overall survival rates were 85.2% (95% CI, 83.5 to 86.8) and 94.3% (95% CI, 93.1 to 95.3), respectively. The cumulative incidence of relapse and postremission nonrelapse mortality was 13.2% (95% CI, 11.6 to 14.8) and 0.6% (95% CI, 0.3 to 1.0), respectively. Random assignment in the SR group showed no significant benefit from pulse therapy. In the IR group, ASP intensification had limited effects. In the HR group, standard block therapy and HD-MTX yielded equivalent outcomes. CONCLUSION: The ALL-B12 trial achieved favorable outcomes in a nationwide cohort by stratifying treatment on the basis of risk and balancing treatment intensity. This study not only demonstrated that existing standard of care can be further refined but also indicated that improvement in outcomes with intensified chemotherapy has reached a plateau.
- Open Access
- 19 December 2023
- Published by Wiley in European Journal of Haematology
- Vol. 112 (4) , 585-593
Rituximab with standard LMB chemotherapy in pediatric high‐risk mature B‐cell non‐Hodgkin lymphoma: A report from the JPLSG B‐NHL14 trial
Background: The benefit of adding rituximab to standard lymphomes malins B (LMB) chemotherapy for children with high‐risk mature B‐cell non‐Hodgkin lymphoma (B‐NHL) has previously been demonstrated in an international randomized phase III trial, to which the Japanese Pediatric Leukemia/Lymphoma Study Group could not participate.Methods: To evaluate the efficacy and safety of rituximab in combination with LMB chemotherapy in Japanese patients, we conducted a single‐arm multicenter trial.Results: In this study, 45 patients were enrolled between April 2016 and September 2018. A total of 33 (73.3%), 5 (11.1%), and 6 (13.3%) patients had Burkitt lymphoma/leukemia, diffuse large B‐cell lymphoma, and aggressive mature B‐NHL, not otherwise specified, respectively. Ten (22.2%) and 21 (46.7%) patients had central nervous system disease and leukemic disease, respectively. The median follow‐up period was 47.5 months. Three‐year event‐free survival and overall survival were 97.7% (95% confidence interval, 84.9–99.7) and 100%, respectively. The only event was relapse, which occurred in a patient with diffuse large B‐cell lymphoma. Seven patients (15.6%) developed Grade 4 or higher non‐hematologic adverse events. Febrile neutropenia was the most frequent Grade 3 or higher adverse event after the pre‐phase treatment, with a frequency of 54.5%.Conclusion: The efficacy and safety of rituximab in combination with LMB chemotherapy in children with high‐risk mature B‐NHL was observed in Japan.
- 19 December 2023
- Published by Wiley in European Journal of Haematology
- Vol. 112 (4) , 585-593
Open AccessRituximab with standard LMB chemotherapy in pediatric high‐risk mature B‐cell non‐Hodgkin lymphoma: A report from the JPLSG B‐NHL14 trial
Background: The benefit of adding rituximab to standard lymphomes malins B (LMB) chemotherapy for children with high‐risk mature B‐cell non‐Hodgkin lymphoma (B‐NHL) has previously been demonstrated in an international randomized phase III trial, to which the Japanese Pediatric Leukemia/Lymphoma Study Group could not participate.Methods: To evaluate the efficacy and safety of rituximab in combination with LMB chemotherapy in Japanese patients, we conducted a single‐arm multicenter trial.Results: In this study, 45 patients were enrolled between April 2016 and September 2018. A total of 33 (73.3%), 5 (11.1%), and 6 (13.3%) patients had Burkitt lymphoma/leukemia, diffuse large B‐cell lymphoma, and aggressive mature B‐NHL, not otherwise specified, respectively. Ten (22.2%) and 21 (46.7%) patients had central nervous system disease and leukemic disease, respectively. The median follow‐up period was 47.5 months. Three‐year event‐free survival and overall survival were 97.7% (95% confidence interval, 84.9–99.7) and 100%, respectively. The only event was relapse, which occurred in a patient with diffuse large B‐cell lymphoma. Seven patients (15.6%) developed Grade 4 or higher non‐hematologic adverse events. Febrile neutropenia was the most frequent Grade 3 or higher adverse event after the pre‐phase treatment, with a frequency of 54.5%.Conclusion: The efficacy and safety of rituximab in combination with LMB chemotherapy in children with high‐risk mature B‐NHL was observed in Japan.
- 27 April 2023
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 62 (7) , 412-422
TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia
Pediatric acute myeloid leukemia (AML) is a poor prognostic subtype of pediatric leukemia. However, the detailed characteristics of many genetic abnormalities are yet to be established in this disease. Although TP53 and RB1 are established as representative tumor suppressor genes in various cancers, alterations of these two genes, especially RB1, have not been characterized in pediatric AML. We performed next‐generation sequencing in 328 pediatric AML patients from the Japanese AML‐05 trial to ascertain TP53 and RB1 alterations, and their prognostic implications. We identified seven patients with TP53 alterations (2.1%) and six patients with RB1 alterations (1.8%). These alterations were found in only patients without RUNX1::RUNX1T1, CBFB::MYH11, or KMT2A rearrangements. TP53 and RB1 were frequently co‐deleted with their neighboring genes PRPF8 and ELF1, respectively. Patients with TP53 alterations had significantly lower 5‐year overall survival (OS; 14.3% vs. 71.4%, p < 0.001) and lower 5‐year event‐free survival (EFS; 0% vs. 56.3%, p < 0.001); similarly, patients with RB1 had significantly lower 5‐year OS (0% vs. 71.8%, p < 0.001) and lower 5‐year EFS (0% vs. 56.0%, p < 0.001) when compared to patients without these alterations. In gene expression analyses, oxidative phosphorylation, glycolysis, and protein secretion were upregulated in patients with TP53 and/or RB1 alterations. Additionally, Kaplan–Meier analysis revealed that high expressions of SLC2A5, KCNAB2, and CD300LF were related to poor OS of non‐core‐binding factor AML patients (p < 0.001, p = 0.001, and p = 0.021, respectively). This study will contribute to the development of risk‐stratified therapy and precision medicine in pediatric AML.
- 27 April 2023
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 62 (7) , 412-422
TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia
Pediatric acute myeloid leukemia (AML) is a poor prognostic subtype of pediatric leukemia. However, the detailed characteristics of many genetic abnormalities are yet to be established in this disease. Although TP53 and RB1 are established as representative tumor suppressor genes in various cancers, alterations of these two genes, especially RB1, have not been characterized in pediatric AML. We performed next‐generation sequencing in 328 pediatric AML patients from the Japanese AML‐05 trial to ascertain TP53 and RB1 alterations, and their prognostic implications. We identified seven patients with TP53 alterations (2.1%) and six patients with RB1 alterations (1.8%). These alterations were found in only patients without RUNX1::RUNX1T1, CBFB::MYH11, or KMT2A rearrangements. TP53 and RB1 were frequently co‐deleted with their neighboring genes PRPF8 and ELF1, respectively. Patients with TP53 alterations had significantly lower 5‐year overall survival (OS; 14.3% vs. 71.4%, p < 0.001) and lower 5‐year event‐free survival (EFS; 0% vs. 56.3%, p < 0.001); similarly, patients with RB1 had significantly lower 5‐year OS (0% vs. 71.8%, p < 0.001) and lower 5‐year EFS (0% vs. 56.0%, p < 0.001) when compared to patients without these alterations. In gene expression analyses, oxidative phosphorylation, glycolysis, and protein secretion were upregulated in patients with TP53 and/or RB1 alterations. Additionally, Kaplan–Meier analysis revealed that high expressions of SLC2A5, KCNAB2, and CD300LF were related to poor OS of non‐core‐binding factor AML patients (p < 0.001, p = 0.001, and p = 0.021, respectively). This study will contribute to the development of risk‐stratified therapy and precision medicine in pediatric AML.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma
Primary central nervous system lymphoma (PCNSL) is an isolated type of lymphoma of the central nervous system and has a dismal prognosis despite intensive chemotherapy. Recent genomic analyses have identified highly recurrent mutations of MYD88 and CD79B in immunocompetent PCNSL, whereas LMP1 activation is commonly observed in Epstein–Barr virus (EBV)-positive PCNSL. However, a lack of clinically representative preclinical models has hampered our understanding of the pathogenic mechanisms by which genetic aberrations drive PCNSL disease phenotypes. Here, we establish a panel of 12 orthotopic, patient-derived xenograft (PDX) models from both immunocompetent and EBV-positive PCNSL and secondary CNSL biopsy specimens. PDXs faithfully retained their phenotypic, metabolic, and genetic features, with 100% concordance of MYD88 and CD79B mutations present in PCNSL in immunocompetent patients. These models revealed a convergent functional dependency upon a deregulated RelA/p65-hexokinase 2 signaling axis, codriven by either mutated MYD88/CD79B or LMP1 with Pin1 overactivation in immunocompetent PCNSL and EBV-positive PCNSL, respectively. Notably, distinct molecular alterations used by immunocompetent and EBV-positive PCNSL converged to deregulate RelA/p65 expression and to drive glycolysis, which is critical for intracerebral tumor progression and FDG-PET imaging characteristics. Genetic and pharmacologic inhibition of this key signaling axis potently suppressed PCNSL growth in vitro and in vivo. These patient-derived models offer a platform for predicting clinical chemotherapeutics efficacy and provide critical insights into PCNSL pathogenic mechanisms, accelerating therapeutic discovery for this aggressive disease.Significance:A set of clinically relevant CNSL xenografts identifies a hyperactive RelA/p65-hexokinase 2 signaling axis as a driver of progression and potential therapeutic target for treatment and provides a foundational preclinical platform.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma
Primary central nervous system lymphoma (PCNSL) is an isolated type of lymphoma of the central nervous system and has a dismal prognosis despite intensive chemotherapy. Recent genomic analyses have identified highly recurrent mutations of MYD88 and CD79B in immunocompetent PCNSL, whereas LMP1 activation is commonly observed in Epstein–Barr virus (EBV)-positive PCNSL. However, a lack of clinically representative preclinical models has hampered our understanding of the pathogenic mechanisms by which genetic aberrations drive PCNSL disease phenotypes. Here, we establish a panel of 12 orthotopic, patient-derived xenograft (PDX) models from both immunocompetent and EBV-positive PCNSL and secondary CNSL biopsy specimens. PDXs faithfully retained their phenotypic, metabolic, and genetic features, with 100% concordance of MYD88 and CD79B mutations present in PCNSL in immunocompetent patients. These models revealed a convergent functional dependency upon a deregulated RelA/p65-hexokinase 2 signaling axis, codriven by either mutated MYD88/CD79B or LMP1 with Pin1 overactivation in immunocompetent PCNSL and EBV-positive PCNSL, respectively. Notably, distinct molecular alterations used by immunocompetent and EBV-positive PCNSL converged to deregulate RelA/p65 expression and to drive glycolysis, which is critical for intracerebral tumor progression and FDG-PET imaging characteristics. Genetic and pharmacologic inhibition of this key signaling axis potently suppressed PCNSL growth in vitro and in vivo. These patient-derived models offer a platform for predicting clinical chemotherapeutics efficacy and provide critical insights into PCNSL pathogenic mechanisms, accelerating therapeutic discovery for this aggressive disease.Significance:A set of clinically relevant CNSL xenografts identifies a hyperactive RelA/p65-hexokinase 2 signaling axis as a driver of progression and potential therapeutic target for treatment and provides a foundational preclinical platform.
- 7 December 2022
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 62 (4) , 202-209
UBTF‐internal tandem duplication as a novel poor prognostic factor in pediatric acute myeloid leukemia
The prognosis of pediatric acute myeloid leukemia (AML) has improved via stratification therapy. However, relapse or death occurs in 30%–40% of cases. Novel genetic factors for pediatric AML need to be elucidated to improve prognosis. We detected recurrent internal tandem duplication in upstream binding transcription factor (UBTF‐ITD) in 1.2% (6/503) of Japanese pediatric patients with de novo AML. No UBTF‐ITD was detected in 175 adult patients with AML or in 65 cell lines that included 15 AML, 39 acute lymphoblastic leukemia, five chronic myeloid leukemia, and six neuroblastoma cell lines. All UBTF‐ITDs were found in exon 13 and shared a duplicated region. UBTF‐ITD was more frequently detected in patients with trisomy 8, FLT3‐ITD, WT1 mutation, and/or high PRDM16 expression (trisomy 8, 3/6; FLT3‐ITD, 5/6; WT1 mutation, 2/6; and high PRDM16 expression, 6/6). Gene expression patterns of patients with UBTF‐ITD were similar to those of patients with NUP98::NSD1 or FUS::ERG. Survival analysis of the AML‐05 cohort revealed that patients with UBTF‐ITD had worse outcomes than those without UBTF‐ITD (3‐year event‐free survival, 20% vs. 55%; 3‐year overall survival, 40% vs. 74%). Moreover, among the 27 patients with trisomy 8, all three patients with UBTF ‐ITD had a poor prognosis resulting in early events (relapse or non‐complete remission) within 1 year. Our findings suggest that UBTF‐ITD may be a novel and significant prognostic factor for pediatric patients with AML.
- 7 December 2022
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 62 (4) , 202-209
UBTF‐internal tandem duplication as a novel poor prognostic factor in pediatric acute myeloid leukemia
The prognosis of pediatric acute myeloid leukemia (AML) has improved via stratification therapy. However, relapse or death occurs in 30%–40% of cases. Novel genetic factors for pediatric AML need to be elucidated to improve prognosis. We detected recurrent internal tandem duplication in upstream binding transcription factor (UBTF‐ITD) in 1.2% (6/503) of Japanese pediatric patients with de novo AML. No UBTF‐ITD was detected in 175 adult patients with AML or in 65 cell lines that included 15 AML, 39 acute lymphoblastic leukemia, five chronic myeloid leukemia, and six neuroblastoma cell lines. All UBTF‐ITDs were found in exon 13 and shared a duplicated region. UBTF‐ITD was more frequently detected in patients with trisomy 8, FLT3‐ITD, WT1 mutation, and/or high PRDM16 expression (trisomy 8, 3/6; FLT3‐ITD, 5/6; WT1 mutation, 2/6; and high PRDM16 expression, 6/6). Gene expression patterns of patients with UBTF‐ITD were similar to those of patients with NUP98::NSD1 or FUS::ERG. Survival analysis of the AML‐05 cohort revealed that patients with UBTF‐ITD had worse outcomes than those without UBTF‐ITD (3‐year event‐free survival, 20% vs. 55%; 3‐year overall survival, 40% vs. 74%). Moreover, among the 27 patients with trisomy 8, all three patients with UBTF ‐ITD had a poor prognosis resulting in early events (relapse or non‐complete remission) within 1 year. Our findings suggest that UBTF‐ITD may be a novel and significant prognostic factor for pediatric patients with AML.